Revvity (RVTY) Barclays 28th Annual Global Healthcare Conference summary

Signals platform and AI integration

• Signals platform includes ChemDraw, Signals One, and Spotfire, serving as core tools for research scientists to design, store, and analyze molecular data.

• AI is viewed as an accelerator, not a disruptor, enhancing the capabilities and efficiency of the Signals suite.

• New launches—BioDesign, LabGistics, and Xynthetica—expand the platform to large molecule design, lab logistics, and operationalizing machine learning models.

• Xynthetica acts as an iOS-like system, enabling access to both proprietary and public machine learning models for research, with a consumption-based revenue model.

• Productization of Xynthetica with partners like Lilly is expected in the second half of the year, with ongoing discussions for broader adoption.

Financial outlook and growth strategy

• Signals business is projected to grow at 9%-11% in the long-range plan, with actual performance trending in the low- to mid-teens APV.

• New launches are expected to drive growth, with a goal to double the Signals business within four to five years.

• Signals revenue model is shifting from seat-based subscriptions to a consumption-based approach, especially with Xynthetica.

• Margin expansion is anticipated, with cost-cutting and operational efficiencies expected to benefit the second half of the year and into 2027.

• Guidance remains conservative, factoring in potential policy headwinds, especially from China, and assumes stable but not robust pharma demand.

Competitive landscape and market dynamics

• BioLegend has gained market share in a depressed reagents market, focusing on service, quality, and scientific partnership.

• Flow cytometry reagents represent about 30% of the total reagents business, with other assays like AlphaLISA and HTRF contributing to growth.

• Long-term reagent programs provide business stability, with growth tied to ongoing pharma and biotech discovery projects.

• The funding environment for biotech is stabilizing, with early signs of renewed investment in innovation and preclinical research.

• M&A activity and competitive shifts are ongoing, but differentiation is driven by scientific innovation and customer collaboration.